[
    [
        {
            "time": "2018-01-01",
            "original_text": "Three Diabetes Clinical Trials to Watch in 2018",
            "features": {
                "keywords": [
                    "diabetes",
                    "clinical trials",
                    "watch"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Three Diabetes Clinical Trials to Watch in 2018",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?",
            "features": {
                "keywords": [
                    "Merck",
                    "Keytruda",
                    "spark"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod",
            "features": {
                "keywords": [
                    "Lilly",
                    "Elanco",
                    "veterinary medicine",
                    "EU nod"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "veterinary"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Dow 30 Stock Roundup: Boeing Q4 Deliveries Up Y/Y, Success for Merck's Keytruda Combo",
            "features": {
                "keywords": [
                    "Dow 30",
                    "Boeing",
                    "Q4 deliveries",
                    "Merck",
                    "Keytruda"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "aerospace",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dow 30 Stock Roundup: Boeing Q4 Deliveries Up Y/Y, Success for Merck's Keytruda Combo",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod",
            "features": {
                "keywords": [
                    "Lilly",
                    "Elanco",
                    "veterinary medicine",
                    "EU nod"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "veterinary"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Wall Street Recommendations for Mylan in January 2018",
            "features": {
                "keywords": [
                    "Wall Street",
                    "recommendations",
                    "Mylan"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Wall Street Recommendations for Mylan in January 2018",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]